A randomised study of CGS 16949A (fadrozole) versus tamoxifen previously untreated postmenopausal patients with metastatic breast cancer

Annals of Oncology

Volumn 7, Issue 5, 1996, Pages 465-469

  Falkson, C I ^a   Falkson, H C ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Breast cancer; Fadrozole; Postmenopausal; Tamoxifen

Indexed keywords

FADROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030035607     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010634     Document Type: Article

References (22)

1. Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 1989; 16: 83-93.
2. Dowsett M, Stein RC, Mehta A et al. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol 1990; 32: 623-34.
3. Steele RE, Mellor LB, Sawyer WK et al. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949 A. Steroids 1987; 50: 147-61.
4. Lipton A, Harvey HA, Demers LM et al. A phase I trial of CGS 16949 A. A new aromatase inhibitor. Cancer 1990; 65: 1279-85.
5. Harvey HA, Lipton A, Santen RJ et al. Clinical trials with the aromatase inhibitor CGS 16949 A in advanced breast cancer - preliminary report. In Jonat W, Santen RJ (eds): Aromatase Inhibition Present and Future. Symposium sponsored by Ciba-Geigy, 15th UICC International Cancer Congress, Hamburg. New Jersey: Parthenon Publishing Group 1991; 89-96.
6. Integrated Trial Report (Clinical and Statistical) CGS 16 949A Protocol 02 - July 1990.
7. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
8. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
9. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
10. Harrington DR, Flemming TR. A class of rank procedures for censored survival data. Biometrika 1982; 69: 553-66.
11. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38: 29-41.
12. Fisher RA. Statistical Methods for Research Workers. Edinburgh: Edinburgh University 1934.
13. Gelber RD, Zelen M. Planning and reporting of clinical trials. In Calabresi P (ed): Medical Oncology: Basic Principles and Clinical Management of Cancer. New York: Macmillan Publishing Company 1985; 406-25.
14. Brodie AMH, Santen RJ. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors. Crit Rev Oncol Hematol 1986; 5: 361-98.
15. Powles TJ. The role of aromatase inhibitors in breast cancer. Semin Oncol 1983; 10: 20-4.
16. Harris AL. Could aminoglutethimide replace adrenalectomy? Breast Cancer Res Treat 1985; 5: 201-11.
17. Stuart-Harris RC, Smith I. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 1984; 11: 189-204.
18. Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. Acta Oncol 1988; 27: 721-8.
19. Gale KE, Andersen JW, Tormey DC et al. Hormonal treatment for metastatic breast cancer - an Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer 1994; 73: 354-61.
20. Iveson TJ, Smith IE, Ahern J et al. CGS 20 267: Phase I results in breast cancer. 1st International Dual Meeting on Basic and Clinical Aspects of Aromatase. Clinical use of Aromatase Inhibitors: Current data and future perspectives. Bologna, June 17-19 1992; 58 (Abstr Book).
21. Falkson G, Raats JI, Falkson HC. A prospective study of two doses of CGS 16949 A hydrochloride, for the treatment of patients with metastatic breast cancer. In Robustelli della Cuna G, Manni A, Pannuti F (eds): Clinical Use of Aromatase Inhibitors. Current Data and Future Perspectives. Pavia: Edimes Edizioni Medico Scietifiche 1994; 159-63.
22. Mauriac L. Randomised trial of the selective aromatase inhibitor formestane (Lentaron) versus tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer. Progress in the Treatment and Palliation of Advanced Breast Cancer. An International Symposium on the Occasion of the European Conference on Clinical Oncology (ECCO) Jerusalem 1993; 6 (Abstr).